NuFund Venture Group Invests in TRIO Pharmaceuticals to Advance Next-Generation Cancer Immunotherapies
Summary
By eliminating these bad actor immunosuppressive cells, TRIO enhances antitumor immunity and unlocks new possibilities in oncology.TRIOs innovative platform is transforming cancer treatment by tackling both tumor cells and the immunosuppressive environment that protects them, said Prasad Sunkara, NuFund member and Deal Lead for TRIO. Their breakthrough therapies, combined with a leadership team that includes industry veterans, represent the type of high-impact innovation NuFund is committed to supporting.TRIO Pharmaceuticals is raising funding to advance its TRAIL Body program through IND-enabling studies. The current $2.2M seed funding round includes investments from Purdue Ventures, NuFund, SeedFolio, Friedman Bioventure, Life Science Angels, and others. This milestone is crucial for positioning us to collaborate with larger pharmaceutical companies and raise future funding rounds.TRIOs ties to Purdue University underscore its commitment to innovation. Formerly Tech Coast Angels San Diego, NuFund has become one of the largest and most active early-stage investor groups, with a focus on supporting transformative startups across industries.